Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults
Conditions: Hypertension Interventions: Drug: CKD-341, D956 Sponsors: Chong Kun Dang Pharmaceutical Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Effect of Isometric and Aerobic Physical Exercise on Blood Pressure Levels in Hypertensive Elderly People
Conditions: Hypertension,Essential; Hypertension Interventions: Other: Group control; Other: Isometric Exercise; Other: Aerobic Exercise Sponsors: Instituto de Cardiologia do Rio Grande do Sul Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Evaluation of Medication Management Service
Conditions: Medication Adherence; Medication Safety; Diabetes Mellitus, Type 2; Hypertension; Polypharmacy; High Risk Medications Interventions: Behavioral: Medication Management Service (MMS) Sponsors: The University of Hong Kong; Hong Kong Jockey Club Charities Trust; Hong Kong Sheng Kung Hui Welfare Council; Hong Kong Young Women ' s Christian Association; Haven of Hope Hospital; Pok Oi Hospital; St. James Settlement; Aberdeen Kai-fong Welfare Association; Health In Action; Lok Sin Tong Benevolent Society, Kowloon Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Conditions: Pulmonary Arterial Hypertension Interventions: Drug: Seralutinib; Device: Gereic Dry Powder Inhaler Sponsors: GB002, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Optimal Medical Treatment of Difficult-to-treat Hypertension
Conditions: Hypertension Interventions: Drug: Phase C: Eplerenone; Drug: Phase C: Spironolactone; Drug: Phase C: Torasemide; Drug: Phase B: Triplixam / Elestar HCT; Diagnostic Test: Phase A: Confirmation of uncontrolled hypertension Sponsors: National Institute of Cardiology, Warsaw, Poland Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Conditions: High Cardiovascular Risk; Hypertension Interventions: Drug: Zilebesiran; Drug: Placebo Sponsors: Alnylam Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Vital Signs Blood Pressure Trial
Conditions: Cardiovascular Diseases; Hypertension; Blood Pressure Interventions: Other: Blood Pressure Cuff, EKG, PPG Sponsors: Stanford University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Conditions: Chronic Kidney Disease and Hypertension Interventions: Drug: Baxdrostat/dapagliflozin; Drug: Dapagliflozin in combination with placebo Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
Conditions: Open-angle Glaucoma; Ocular Hypertension Interventions: Drug: Bimatoprost Ophthalmic Solution, 0.01%; Drug: LUMIGAN ® (bimatoprost ophthalmic solution) 0.01% Sponsors: Amneal Pharmaceuticals, LLC; CBCC Global Inc.; Amneal EU, Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
Evaluation of cats tonometer prism in lasik subjects
Conditions: Glaucoma; Ocular Hypertension; Normal Tension Glaucoma Interventions: Device: This is observational IOP measurement Sponsors: Intuor Technologies, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension
Conditions: Hypertension Interventions: Dietary Supplement: Low dose; Dietary Supplement: High dose; Dietary Supplement: Placebo Sponsors: Universitat de Lleida; Pharmactive Biotech Products S.L.U Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Evaluation of the Performance of Direct Portal Pressure Measurement by Endoscopic Ultrasound in a Large Cohort of Patients With Advanced Chronic Liver Disease of Different Etiologies and Newly Diagnosed Clinically Significant Portal Hypertension (EVADIPP)
Conditions: Portal Hypertension Interventions: Device: EUS PPG measurement Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Conditions: Liver Cirrhosis; Hepatic Cell Carcinoma; Portal Hypertension Interventions: Drug: Injection of a gadolinium contrast agen; Drug: Radiotracer Injection; Diagnostic Test: Imaging Sponsors: Massachusetts General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
Conditions: Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension Interventions: Drug: Experimental group: Patients will be treated with carvedilol.; Other: Control group: Patients will receive a placebo. Sponsors: University Hospital, Tours; Centre Hospitalier Universitaire Amiens Picardie; Centre Hospitalier Universitaire Angers; Assistance Publique Hopitaux Paris BEAUJON; Centre Hospitalier Universitaire Caen; Centre Hospitalier intercommunal de Cr éteil; Hospices Civils de Lyon; Centre Hospitalier Universitaire Grenoble; Centre Hospitalier Universitaire Haut Lévêque; Centre Hospit...
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
Conditions: Arterial Hypertension; HTN Interventions: Drug: Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg; Drug: Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg; Drug: Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg Sponsors: Servier Russia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
